DexCom, Inc. (DXCM): Price and Financial Metrics


DexCom, Inc. (DXCM)

Today's Latest Price: $350.81 USD

10.61 (-2.94%)

Updated Jan 27 3:41pm

Add DXCM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 188 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

DXCM Stock Summary

  • DXCM's current price/earnings ratio is 150.18, which is higher than 94.18% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for DXCM is currently 77.59, higher than 93.44% of US stocks with positive operating cash flow.
  • Over the past twelve months, DXCM has reported earnings growth of -341.82%, putting it ahead of merely 5.72% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Dexcom Inc are ANSS, GLW, TTD, RMD, and KEYS.
  • DXCM's SEC filings can be seen here. And to visit Dexcom Inc's official web site, go to www.dexcom.com.

DXCM Stock Price Chart Interactive Chart >

Price chart for DXCM

DXCM Price/Volume Stats

Current price $350.81 52-week high $456.23
Prev. close $361.42 52-week low $182.07
Day low $350.41 Volume 784,745
Day high $361.21 Avg. volume 972,994
50-day MA $350.18 Dividend yield N/A
200-day MA $381.32 Market Cap 33.69B

DexCom, Inc. (DXCM) Company Bio


DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.

DXCM Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$350.81$413.42 14%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dexcom Inc. To summarize, we found that Dexcom Inc ranked in the 54th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Dexcom Inc ended up being:

  • The company's balance sheet shows it gets 95% of its capital from equity, and 5% of its capital from debt. Notably, its equity weight is greater than 71.01% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The company's compound free cash flow growth rate over the past 5.5 years comes in at 0.84%; that's greater than 88.35% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 16.63% of US stocks with free cash flow have a lower reliance on debt in their capital structure.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%12%
1%13%
2%14%
3%16%
4%17%
5%18%

FONR, REGN, UNH, CMD, and FZMD can be thought of as valuation peers to DXCM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about Dexcom Inc that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Smart Medical Devices Market Prophesied to Grow at a Faster Pace by 2027 | Abbott Laboratories, Apple, Inc., Medtronic, Dexcom, Fitbit, F. Hoffmann-La Roche, Johnson & Johnson, Medtronic, NeuroMetrix, Samsung Electronics, and Sonova International

Increasing launch of wearable medical devices is expected to propel growth of Asia Pacific smart medical devices market over the forecast period. For instance, in January 2020, VivaLNK, a China-based provider of connected healthcare solutions for in-patient and remote patient

OpenPR | January 22, 2021

Abbott vs Dexcom: Which “Strong Buy” Stock Could Deliver Higher Returns in 2021?

With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is growing rapidly worldwide—sedentary lifestyles being a key reason for that. A recent report by the World Health Organization (WHO) revealed that deaths from diabetes surged 70% globally between 2019 and 2020. Abbott and Dexcom are some of the names that are developing diabetes monitoring systems. Using the TipRanks Stock Comparison tool, we will place Abbott and Dexcom alongside each other and pick the stock reflecting a more compelling play.

Sirisha Bhogaraju on TipRanks | January 19, 2021

Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time.

Business Wire | January 19, 2021

Global Continuous Glucose Monitoring (CGM) Sensors Market 2021 | Medtronics, Dexcom, Senseonics, WaveForm Technologies, Inc., Abbott Diabetes Care Inc, Arkal Medical, Inc., Ascensia Diabetes Care Holdings AG, Biorasis Inc, Debiotech SA and many more.

InsightAce Analytic Pvt. Ltd. features the release of the market research report on “Global Continuous Glucose Monitoring (CGM) Sensors Market Assessment – Industry Analysis, Competitive Analysis, COVID 19 Impact Analysis, and Revenue & Volume Forecast Till 2028” According to the

OpenPR | January 18, 2021

Is DexCom (NASDAQ:DXCM) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | January 18, 2021

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo -3.17%
3-mo 4.63%
6-mo -19.45%
1-year 49.32%
3-year 504.01%
5-year 392.16%
YTD -5.11%
2020 69.02%
2019 82.59%
2018 108.75%
2017 -3.87%
2016 -27.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7734 seconds.